瑞舒伐他汀对代谢综合征患者载脂蛋白B／载脂蛋白A1的影响

Effect of rosuvastatin on ApoB/ApoA1 in patients with metablic syndrome

目的观察瑞舒伐他汀对代谢综合征（MS）患者载脂蛋白B／载脂蛋白A1（ApoB／ApoAl）的影响。方法将60例MS患者分为两组，瑞舒伐他汀组（30例）给予舒夫坦10mg／d治疗，阿托伐他汀组（30例）给予立普妥20mg／d治疗。随访12周，观察研究前后血脂、血糖、血压、尿白蛋白排泄率（UAER）、体重指数（BMI）、肝功能、肾功能、肌酸激酶、血常规的变化。结果治疗4周后两组分别较治疗前ApoB／ApoA1、ApoB、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL—C）、甘油三酯（TG）显著下降（P均〈0．01），ApoA1、高密度脂蛋白胆固醇（HDL—C）有增高趋势，但差异无统计学意义，余指标两组比较差异无统计学意义。治疗12周后两组分别较治疗前及治疗4周后ApoB／ApoA1、ApoB、TC、LDL-C、TG及收缩压、舒张压、UAER显著下降（P均〈0．01），ApoA1、HDL—C有继续增高趋势，但差异无统计学意义，余指标两组比较差异无统计学意义。结论瑞舒伐他汀可改善MS患者的血脂紊乱，降低ApoB／ApoA1比值。

Objective To observe the effect of rosuvastatin on ApoB/ApoA1 in patients with metablic syndrome（MS）. Methods Sixty patients with MS were divided into two groups, 30 patients in rosuvastatin group received schufftan 10 mg/d and 30 cases in atorvastatin group received lipitor 20 mg/d. The blood lipids, plasma glucose, blood pressure, urinary albumin excretion rates（UAER） , body mass index（BMI） , hepatic and renal function, creatine kinase （CK） , blood routine were measured before and after 4-weeks, 12-weeks treatment. Results After 4-weeks treatment, the plasma levels of ApoB/ApoA1, ApoB, TC, LDL-C, TG decreased obviously in both groups （P 〈 0. 01）. The plasma levels of ApoA1 and HDL-C tended to increase, but there were no significant differences, other parame- ters were not signifeantly different, the above-mentioned indicators between the two groups at the 4th- week follow-up were not significantly different. After 12-weeks treatment, the plasma levels of ApoB/ ApoA1, ApoB, TC, LDL-C, TG decreased significantly than before treatment and after 4-week follow-up in the two groups, respectively （P 〈 0.01 ）, but there were no statistically significant differences in ApoA1, HDL-C, the plasma level of ApoB/ApoA1, ApoB, TC, LDL-C in the rosuvastatin group were lower than those in the atorvastatin group at the 12th-week follow-up （P 〈 0. 05）. Conclusions Rosuv- astatin can ameliarate dyslipidemia in MS patients and reduce ApoB/ApoA1 ratio.